Drugs / E-selectin
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00069069 | Oct 2003 → May 2018 | transient ischemic attack, transient refractive change | National Institute of Neurological Disorders and Stroke (NINDS) | Withdrawn | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00012454 | Mar 2001 → Feb 2004 | transient ischemic attack | National Institute of Neurological Disorders and Stroke (NINDS) | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | E-selectin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00069069 ↗ |
| Modality | Protein / enzyme biologic | “This study will test the safety and effectiveness of a protein called E-selectin, given as a nasal spray” NCT00012454 ↗ |
| Route | Intranasal | “intranasal recombinant human E-selectin” NCT00069069 ↗ |